ArticleHeliyon2024
Efficacy and safety of integrated traditional Chinese and Western medicine for rheumatoid arthritis-interstitial lung disease: A systematic review and meta-analysis.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Molding the Pain into Porcelain: The Silent Resilience of Arthritic Hands in Hong Kong's Ceramic Studios.Healthcare (Basel, Switzerland) · 2026Article
- SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches.Journal of inflammation research · 2026Review
- Advances in Drug Research Targeting Neutrophils for the Treatment of Rheumatoid Arthritis.Current rheumatology reports · 2025Review
- Expert consensus on the advantages of traditional Chinese medicine in the treatment of rheumatoid arthritis.Chinese medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the efficacy and safety of integrated traditional Chinese and Western medicine(TCM-WM) for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Materials and methods: An independent search of electronic databases (PubMed, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, OVID Medline, China National Knowledge Infrastructure, WanFang Data, VIP Data databases, and China Biology Medicine disc) from inception to June 25, 2024 was performed to identify studies treating RA-ILD that used combined Chinese and Western medicine treatment compared to Western medicine. Two researchers independently audited each article, and the quality was assessed using the Cochrane Risk of Bias Assessment Tool 2 and the modified Jadad. Meta-analyses were performed using Review Manager 5.4 and Stata 16.0 software to analyze data. Sample certainty and conclusiveness of evidence were assessed using the Grading of Recommendations Assessment, Development, and Evaluation Profiler (GRADEPRO) and trial sequential analysis(TSA) 0.9.5.10 beta. Results: Eighteen randomised controlled trials (RCT), including 1353 patients, were abstracted. Integrated traditional Chinese and Western medicine was significantly more effective than Western medicine in improving lung function in patients with rheumatoid arthritis-associated interstitial lung disease, including forced vital capacity (FVC) (Standardized Mean Difference (SMD) = 1.44, 95 % CI 0.93 to 1.95, Conclusion: Current evidence shows that combined traditional Chinese medicine is effective and safe for rheumatoid arthritis-associated interstitial lung disease compared with Western medicine alone. The sample size for inclusion concerns may require the inclusion of more randomised trials in the future to validate our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.